LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-TAE684 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3927 | 4168 | 0.9420 | 0.9251 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3458 | 4168 | 0.8295 | 0.7753 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2443 | 4168 | 0.5857 | 0.4215 |
| SK-BR-3 | NVP-TAE684 | 10 | uM | LJP6 | 72 | hr | 1401 | 870 | 4168 | 0.2092 | -0.2623 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4452 | 4245 | 1.0504 | 1.0644 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1099 | 4168 | 0.2640 | -0.1438 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3015 | 4245 | 0.7101 | 0.6132 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1013 | 4168 | 0.2432 | -0.1864 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1329 | 4245 | 0.3136 | -0.0336 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1081 | 4168 | 0.2594 | -0.1524 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1231 | 4245 | 0.2920 | -0.0769 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 934 | 4168 | 0.2242 | -0.2274 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1086 | 4245 | 0.2561 | -0.1492 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 809 | 4168 | 0.1942 | -0.2949 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP5 | 72 | hr | 1401 | 1063 | 4245 | 0.2506 | -0.1615 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 1401 | 696 | 4168 | 0.1674 | -0.3605 |
| SK-BR-3 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4426 | 4168 | 1.0614 | 1.0766 |
| SK-BR-3 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 4239 | 4168 | 1.0170 | 1.0215 |
| SK-BR-3 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4279 | 4168 | 1.0268 | 1.0330 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4453 | 4168 | 1.0696 | 1.0874 |
| SK-BR-3 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4313 | 4168 | 1.0368 | 1.0452 |
| SK-BR-3 | PD173074 | 10 | uM | LJP6 | 72 | hr | 1401 | 2324 | 4168 | 0.5576 | 0.3794 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3728 | 4245 | 0.8792 | 0.8459 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 3970 | 4245 | 0.9346 | 0.9163 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3954 | 4245 | 0.9318 | 0.9135 |